Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dicloxacillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 4/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.89 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.84 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 4/20 | 0.82 |
| ▸ | HPGD | P15428 | 3/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicloxacillin SCHEMBL5595924 | 1.00 | ABCB11 (0.98) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL5549845 | 0.99 | ABCB11 (0.97) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL11407716 | 0.99 | ABCB11 (1.00) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL11407710 | 0.99 | ABCB11 (1.00) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL11407708 | 0.99 | ABCB11 (1.00) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL8727180 | 0.99 | ABCB11 (1.00) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL23955 | 0.99 | ABCB11 (1.00) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL41517 | 0.98 | ABCB11 (0.98) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL28540896 | 0.98 | ABCB11 (0.98) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA | |
| Dicloxacillin SCHEMBL28536434 | 0.98 | ABCB11 (0.98) | ABCB11CYP1A2SLCO1B3SLCO1B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| EP-1827408-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | Nu-Tein Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1827400-A2 | TOPICAL SKIN PATCH CONTAINING XANTHOPHYLLS | Nu-Tein Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1814540-A2 | COMPOSITIONS USEFUL TO TREAT OCULAR NEOVASCULAR DISEASES AND MACULAR DEGENERATION | Nu-Tein Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| WO-2006062740-A2 | TOPICAL SKIN PATCH CONTAINING XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006060475-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006055526-A2 | COMPOSITIONS USEFUL TO TREAT OCULAR NEOVASCULAR DISEASES AND MACULAR DEGENERATION | NU-TEIN CO., INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | ABCB11 3768/4885CYP1A2 2767/4885SLCO1B3 1727/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | ABCB11 218/4885CYP1A2 4314/4885SLCO1B3 290/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | ABCB11 100/4885CYP1A2 1391/4885SLCO1B3 104/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | ABCB11 558/4885CYP1A2 1109/4885SLCO1B3 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.